Alzamend Neuro, Inc. (ALZN)

USD 1.23

(-4.65%)

Market Cap (In USD)

6.68 Million

Revenue (In USD)

-

Net Income (In USD)

-9.94 Million

Avg. Volume

1.66 Million

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.06-15.06
PE
-
EPS
-
Beta Value
-0.038
ISIN
US02262M4078
CUSIP
02262M308
CIK
1677077
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Stephan Jackman
Employee Count
-
Website
https://www.alzamend.com
Ipo Date
2021-06-15
Details
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.